• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The (-)-enantiomer of the compound of formula (I): <CHEM> and its pharmaceutically-acceptable salts, are effective anti-depressant agents.
    公开号:SU1068034A3
    申请号:SU813355735
    申请日:1981-11-13
    公开日:1984-01-15
    发明作者:Джо Фостер Бенни；Ральф Лаваньино Эдвард
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

    ABOUT
    but
    00
    about 00
    four
    As a result, receive 359 g of salt, so pl. 128-129c. The product is recrystallized again from the same solvent system, with the result that 326 g of salt, having a high degree of purity, are obtained. The purified salt is diluted with 2 liters of water and the solution is treated with sodium carbonate.
    The resulting solution is extracted twice with 1 liter of diethyl ether, the organic layers are combined, dried with anhydrous sulfate, sodium, then gaseous hydrogen chloride is bubbled through the solution until the solution gives an acid reaction to the pH indicator. Next, the salt is precipitated and recrystallized from 500; ml of dichloromethane; 1.5 l of ethyl acetate; vigorously boil the mixture until a precipitate begins; At this point, 1 ml of diethyl ether is added. Next, the mixture is cooled and filtered, the precipitate is dried and receive 209 g of hydrochloride; . (-) - N-methyl-3- (2-methylphenoxy) -3-phenylpropylamine, t-pl. 165-168 C. The product is recrystallized from the same solvent system, resulting in 180 g of {-) - N-methyl-3- (2-methylphenoxy) -3-phenylpropylamine hydrochloride, m.p. 165167 C. Optical rotation was 30 ot -37, oSTs- -181,3. Froze (-) N-Methyl-3- (2-methylphenoxy) -3-fenylpropylamine hydrochloride.
    A 3.05 g portion of racemic N-methyl-3- (2-methylphenoxy) 3-phenylpropylamine hydrochloride is dissolved in 50 ml of water and the solution is treated with sodium bicarbonate. The solution is extracted with three 50 ml portions of diethyl ether and the organically combined layers are washed twice with 20 ml portions of water. The solution is dried with magnesium sulfate and concentrated under vacuum to a solid. The residue is dissolved in 100 ml of benzene and 1.5 g of L - (+} - almond acid is added. The solution is then stirred in
    64 hours at 23 ° C and then concentrated under vacuum to a solid, to which 100 ml of 50 xylene is added. The solution is kept until the precipitation stops. The solid is filtered and recrystallized from 20 ml of xylene. The product is then suspended in water and the suspension 55 is alkalinized by the addition of ammonium hydroxide to obtain the free base, which is then extracted with two 20 ml portions of diethyl ether. The organic layers 60 are washed with two 50 ml portions of water, dried over magnesium sulfate and treated with gaseous hydrogen chloride. The hydrochloride obtained is recrystallized from 10 MP of dichloromethane and 30 ml of ethyl acetate by adding 50 ml of diethyl ether. Obtain 90 mg of the desired product, so pl. 156-157 ° C. Optical rotation is d -29.3; оС -146,02 °
    The compound obtained in accordance with the inventive method has antidepressant activity, as well as the racemate from which it is derived. The tests described below demonstrate the high efficacy of the obtained compound compared with the racemate and the corresponding (+) - enantiomer. It is known that one of the causes of depression is the accumulation of inadequate monoamines in the body, the most important of which are norepinephrine, serotonin and dopamine. SUBSTANCE: compounds capable of inhibiting the formation of these monoamines.
    Inhibition of monoamine is measured in vitro using the method of Wong and Bimaster. According to this method, Sprague-Lod male rats weighing 110-150 g are decapitated, the brain is extracted and analyzed. Crude synaptosome preparations are prepared from 10% homogenates of individual brain regions in a 0.32% M sucrose solution and 10 mm glucose solution using differential centrifugation according to the procedure described by Gray and Whittaker. It was found that synaytozomas isolated from hypothalamus accumulated (H) norepinephrine in the amount of 3.9 10 2 mol / mg of protein when tested without any preparation contained in control experiments. The addition of the subject compound to synaptosome preparations resulted in a decrease in the absorption of monoamine, as shown below.
    Concentration, M Absorption,
    mol / mg protein
    -1-9
    3.1-10-:
    1-10
    , -42
    2-10-9
    .2,2-10
    --f2 3-10-9 3.1-10 -12
    10-10-9 1.4-10 -12
    ZOYU 1,0-10 -12
    50-10 0.9-10 .100-10 0.8-10
    The data presented were plotted on a logarithmic scale to determine the concentration of the compound that inhibited half of the absorption activity. This value (value) was 4 -10 M.
    A similar test was carried out for the (+) - enantiomer of the described compound and for the racemic mixture. 1C5Q — the value for the (+) - enantiomer was 40–10 M, and for the racemic mixture, 9–10 M.
    In this case, the ability of the proposed compound to suppress the absorption of norepinephrine is about 10 times greater than the activity of the corresponding (-H) -enantiomer.
    Using the same procedure, the) bq-compound was determined to target (n) serotonin and (Zn) dopamine. It has been reported that the proposed compound absorption of norepinephrine is much more effective compared with asp (gim monoamine). 1C is the value for absorbing dopa and serotomine, respectively. Thus, the proposed compound is selective in its action inhibited the absorption of norepinephrine.
    more effective compared to other monoamines. Many known antidepressants also inhibit the absorption of norepinephrine most effectively.
    The proposed compound has also been studied in part iero of antihslergic activity. In line with this, the anti-Sinergic activity is only 1/6 of the corresponding activity of the (+) - enantiomer and only 1/3 of the racemate. So plasters; The likelihood of anticholinergic side effects of the proposed compound is much less than that of the corresponding (+) - enantiomer or racemate.
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING HYDROCHLORIDE (-) - ENANTIOMER 3-ARILOXY-3FENDLPROPYLAMINE of formula I
    about. in that the racemate of the compound of formula (I) is reacted with an optically active organic (+) - acid such as L - (+) - mandelic, the resulting (+) (-) - is separated a salt from (+) (+) - salt by fractional crystallization from an organic solvent such as xylene or a mixture of dichloromethane ethyl acetate, separated by (+) (-) - g salt is treated with a strong inorganic base such as sodium carbonate or ammonium hydroxide, and the desired product is isolated in the form of hydrochloride.
    SU <„, 1068034
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1068034A3|1984-01-15|Process for preparing 3-aryloxy-3-phenylpropylamine|-enanthiomer 3-aryloxy-3-phe
    RU2172315C1|2001-08-20|METHOD OF PREPARING RACEMIC OR OPTICALLY ACTIVE METHYL | | PYRIDIN-5-YL) ACETATES OR SALTS THEREOF
    KR20060036923A|2006-05-02|Method for the production of substituted 3-aryl-butyl-amine compounds
    US3213106A|1965-10-19|Process of racemizing optically active alpha acids
    EP0688760B1|1999-06-09|Addition salts of acyl-amino acids and alpha-aryl-amines and process for the optical resolution of alpha-arylamines
    EP0147279B1|1987-03-04|Process for the preparation of diamino-alcohols
    US20060211772A1|2006-09-21|Processes for the preparation of atomoxetine hydrochloride
    US6391914B1|2002-05-21|Optically active aminopentane derivatives
    US3381031A|1968-04-30|Resolution of racemic amino acids
    CA1256902A|1989-07-04|Processes for the preparation of nitrosamine-free n,n- disubstituted nitroaromatic amines and for thestabilization of these compounds against theformation of nitrosamines
    EA011409B1|2009-02-27|Process for the preparation of chirally pure “h” nateglinide
    US2214034A|1940-09-10|Racemization of optically active compounds
    FI73663B|1987-07-31|PROCEDURE FOR EXAMINATION OF RACEMATET | -2-AMINO-1-PHENYLPROPAN-1-OL I ISOMERER.
    US10233144B2|2019-03-19|Crystalline form of AHU377, preparation method and use thereof
    US20140121259A1|2014-05-01|Novel crystalline asenapine hydrochloride salt forms
    US4076745A|1978-02-28|Process for calcium salts α-ketocarboxylic acids
    FI72313B|1987-01-30|EXTERNAL REQUIREMENT FOR RACEMATING S- | - | -CYSTEIN I ISOMERER |
    US5171885A|1992-12-15|L-buthionine-S-sulfoximine and L-buthionine-R-sulfoximine
    RU2174510C2|2001-10-10|Hydrochlorides of substituted acetylenic aminoalcohol-active and low-toxic haloperidol antagonists
    Markgraf et al.1990|Steric course of lactonization in the deamination of glutamic acid: an organic mechanism experiment
    US3085110A|1963-04-09|Resolution of n-d-and n-1-sec-butylcyclo-hexylamine by methyl hydrogen di-benzoyl-d tartrate
    JP2823679B2|1998-11-11|Method for producing optically active 2-methylpiperazine
    FI73976C|1987-12-10|Process for distributing the racemate S- | - | -cysteine in isomers
    EP0171616A1|1986-02-19|The use of alpha-amino-epsilon-caprolactam as a resolving agent for N-acetylindoline-2-carboxylic acid and method for preparing optically active N-acetylindoline-2-carboxylic acid
    JP2917495B2|1999-07-12|Method for producing optically active 1,2-propanediamine
    同族专利:
    公开号 | 公开日
    FI77018B|1988-09-30|
    EP0052492A1|1982-05-26|
    DK161887B|1991-08-26|
    ES507142A0|1982-08-16|
    KR830007508A|1983-10-21|
    DE3162445D1|1984-04-05|
    IL64288A|1985-04-30|
    JPS57114555A|1982-07-16|
    ZA817863B|1983-06-29|
    AU7742781A|1982-05-20|
    PT73982A|1981-12-01|
    EG15458A|1986-09-30|
    CS227019B2|1984-04-16|
    JPH037250A|1991-01-14|
    AU540707B2|1984-11-29|
    IL64288D0|1982-02-28|
    RO83309B|1984-02-28|
    MY8700709A|1987-12-31|
    EP0052492B1|1984-02-29|
    JPH0369885B2|1991-11-05|
    AT6422T|1984-03-15|
    FI813589L|1982-05-15|
    HU185475B|1985-02-28|
    FI77018C|1989-01-10|
    JPH046698B2|1992-02-06|
    DD201139A5|1983-07-06|
    CY1350A|1987-04-24|
    JPH046699B2|1992-02-06|
    IE52170B1|1987-07-22|
    DK161887C|1992-03-16|
    ES8206440A1|1982-08-16|
    DK502781A|1982-05-15|
    RO83309A|1984-02-21|
    IE812661L|1982-05-14|
    HK16087A|1987-02-27|
    NZ198953A|1984-10-19|
    PT73982B|1983-11-23|
    GB2087883A|1982-06-03|
    JPH037251A|1991-01-14|
    GR75395B|1984-07-13|
    PL233786A1|1982-05-24|
    CA1181430A|1985-01-22|
    PH17424A|1984-08-08|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4194009A|1974-01-10|1980-03-18|Eli Lilly And Company|Aryloxyphenylpropylamines for obtaining a psychotropic effect|
    US4018895A|1974-01-10|1977-04-19|Eli Lilly And Company|Aryloxyphenylpropylamines in treating depression|
    JPS5283811A|1976-01-01|1977-07-13|Lilly Co Eli|Aryloxy phenyl propylamines and their salts|
    GB1596033A|1978-04-25|1981-08-19|Boots Co Ltd|- ethylamine|
    JPS6320817B2|1978-07-28|1988-04-30|Nippon Iyakuhin Kogyo Kk|
    IT1113029B|1979-03-01|1986-01-20|Simes|PROCESS FOR THE SEPARATION OF THE TWO OPTICAL ISOMERS OF MOPROLOL AND PHARMACEUTICAL COMPOSITIONS OF THE LEVOGIRO ANTIPOD|US4777291A|1985-02-27|1988-10-11|Eli Lilly And Company|Racemization process|
    US5112619A|1985-11-12|1992-05-12|Eli Lilly And Company|Orally administerable sustained release pharmaceutical formulation|
    US4797286A|1985-11-12|1989-01-10|Eli Lilly And Company|Orally administerable sustained release pharmaceutical formulations|
    GB8823405D0|1988-10-05|1988-11-09|Erba Carlo Spa|Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines|
    DK258389D0|1989-05-26|1989-05-26|Ferrosan As|ARYLOXYPHENYL PROPYLAMINES, THEIR PREPARATION AND USE|
    PH30083A|1991-02-25|1996-12-27|Lilly Co Eli|Treatment of lower urinary tract disorders|
    CA2112487C|1991-06-26|2003-04-15|James W. Young|Method and compositions for treating emesis, nausea and other disorders using optically pure r ondansetron|
    CA2123704C|1991-11-15|2003-01-21|James W. Young|Methods and compositions utilizing pure sisomer fluoxetine|
    EP0661970A1|1991-11-26|1995-07-12|Sepracor, Inc.|Methods and compositions for treating hypertension, angina and other disorders using optically pureamlodipine|
    EP0576766A1|1992-06-29|1994-01-05|Novo Nordisk A/S|Propanolamine derivatives, their preparation and use|
    TW344661B|1993-11-24|1998-11-11|Lilly Co Eli|Pharmaceutical composition for treatment of incontinence|
    US8071128B2|1996-06-14|2011-12-06|Kyowa Hakko Kirin Co., Ltd.|Intrabuccally rapidly disintegrating tablet and a production method of the tablets|
    EP1181015A2|1999-03-01|2002-02-27|Sepracor Inc.|Methods for treating apnea and apnea disorders using optically pure rondansetron|
    JP4625637B2|2002-02-22|2011-02-02|シャイアエルエルシー|Active substance delivery system and method for protecting and administering an active substance|
    AU3219800A|1999-03-29|2000-10-16|Eli Lilly And Company|Stereospecific method for preparing tomoxetine and intermediates thereof|
    US6541668B1|1999-04-09|2003-04-01|Eli Lilly And Company|Methods for preparing 3-arloxy-3-arylpropylamines and intermediates thereof|
    DE19955190A1|1999-11-16|2001-06-21|Sanol Arznei Schwarz Gmbh|Stable salts of novel derivatives of 3,3-diphenylpropylamines|
    US9358214B2|2001-10-04|2016-06-07|Adare Pharmaceuticals, Inc.|Timed, sustained release systems for propranolol|
    GB0229583D0|2002-12-19|2003-01-22|Cipla Ltd|A process for preparing duloxetine and intermediates for use therein|
    US8367111B2|2002-12-31|2013-02-05|Aptalis Pharmatech, Inc.|Extended release dosage forms of propranolol hydrochloride|
    US8545881B2|2004-04-19|2013-10-01|Eurand Pharmaceuticals, Ltd.|Orally disintegrating tablets and methods of manufacture|
    ES2313387T3|2004-06-28|2009-03-01|Teva Pharmaceutical Fine Chemicals S.R.L.|ISOLATED ATOMOXETINE IMPURITY, PROCEDURE FOR THE PREPARATION OF ATOMOXETINE IMPURITIES AND ITS USE AS REFERENCE PATTERNS.|
    US7439399B2|2004-06-28|2008-10-21|Teva Pharmaceutical Fine Chemicals|Processes for the preparation of atomoxetine hydrochloride|
    US7473804B2|2004-07-22|2009-01-06|Teva Pharmaceutical Fine Chemicals S.R.L.|Polymorphs of atomoxetine hydrochloride|
    US8747895B2|2004-09-13|2014-06-10|Aptalis Pharmatech, Inc.|Orally disintegrating tablets of atomoxetine|
    US9884014B2|2004-10-12|2018-02-06|Adare Pharmaceuticals, Inc.|Taste-masked pharmaceutical compositions|
    NZ589750A|2004-10-21|2012-07-27|Aptalis Pharmatech Inc|Taste-masked pharmaceutical compositions with gastrosoluble pore-formers|
    WO2006108120A1|2005-04-05|2006-10-12|Teva Pharmaceutical Fine Chemicals S.R.L.|Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability|
    EP1889828A1|2005-04-05|2008-02-20|Teva Pharmaceutical Fine Chemicals S.R.L.|Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability|
    US9161918B2|2005-05-02|2015-10-20|Adare Pharmaceuticals, Inc.|Timed, pulsatile release systems|
    US7485754B2|2005-07-08|2009-02-03|Apotex Pharmachem Inc.|Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers|
    CZ2005473A3|2005-07-21|2006-02-15|Zentiva, A. S|Process for preparing -N-methyl-3--3-phenylpropylamine hydrochloride |
    EP1798215A1|2005-12-14|2007-06-20|SOLMAG S.p.A.|Polymorph of atomoxetine hydrochloride in crystalline form|
    ITMI20061987A1|2006-10-16|2008-04-17|Archimica Srl|PROCESS FOR THE SYNTHESIS OF ARYLOSSIPROPYLAMINES AND HETERARYLOSOSIPROPYLAMINES.|
    WO2008062473A1|2006-10-31|2008-05-29|Cadila Healthcare Limited|Process for preparing atomoxetine hydrochloride|
    CN100430370C|2006-11-03|2008-11-05|华东理工大学|Propylamine derivative and its application in preparing tomocetin|
    WO2009141833A2|2008-04-17|2009-11-26|Ind-Swift Laboratories Limited|An improved process for synthesizing highly pure atomoxetine|
    AU2010325746B2|2009-12-02|2016-02-25|Adare Pharmaceuticals S.R.L.|Fexofenadine microcapsules and compositions containing them|
    SI2838510T1|2013-11-08|2016-11-30|Eli Lilly And Company Lilly Corporate Center|Atomoxetine solution|
    GR1008531B|2014-03-21|2015-07-13|Λαμδα Φαρμακευτικα Εργαστηρια Εφαμροσμενης Ερευνας Και Αναπτυξης Α.Ε.,|Oral solution comprising atomoxetine hydrochloride|
    EP3069715A1|2015-03-20|2016-09-21|Salmon Pharma GmbH|Immediate release dosage forms of Atomoxetine|
    CN106916074A|2017-02-14|2017-07-04|万特制药有限公司|The preparation of tomoxetine hydrochloride|
    CN110294680A|2018-03-22|2019-10-01|北京深蓝海生物医药科技有限公司|A kind of preparation method in levels Moses spit of fland|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US20649880A| true| 1980-11-14|1980-11-14|
    [返回顶部]